{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:29:03Z","timestamp":1794086943993,"version":"4.8.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05045-2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:25:05Z","timestamp":1782195905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin in ADPKD with suspected IgA nephropathy: antiproteinuric response without adverse events"],"prefix":"10.1186","volume":"27","author":[{"given":"Sindi","family":"Uruci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tanzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Bianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Paolisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiana","family":"Kola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana Italia","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Catania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Barruscotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo Fernando","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Livia","family":"Lanzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa Sciarrone","family":"Alibrandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"8","key":"5045_CR1","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/ndt\/gfw240","volume":"32","author":"CJ Willey","year":"2017","unstructured":"Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transpl. 2017;32(8):1356\u201363. https:\/\/doi.org\/10.1093\/ndt\/gfw240 . PMID: 27325254; PMCID: PMC5837385.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"5045_CR2","doi-asserted-by":"publisher","first-page":"e0190430","DOI":"10.1371\/journal.pone.0190430","volume":"13","author":"A Solazzo","year":"2018","unstructured":"Solazzo A, Testa F, Giovanella S, Busutti M, Furci L, Carrera P, Ferrari M, Ligabue G, Mori G, Leonelli M, Cappelli G, Magistroni R. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE. 2018;13(1):e0190430. https:\/\/doi.org\/10.1371\/journal.pone.0190430 . PMID: 29338003; PMCID: PMC5770025.","journal-title":"PLoS ONE"},{"key":"5045_CR3","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD). Kidney Int. 2025;107(2 Suppl):S1\u2013239. https:\/\/doi.org\/10.1016\/j.kint.2024.07.009. PMID: 39848759.","DOI":"10.1016\/j.kint.2024.07.009"},{"key":"5045_CR4","doi-asserted-by":"publisher","unstructured":"Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol. 2002;13(9):2384\u201398. https:\/\/doi.org\/10.1097\/01.asn.0000028643.17901.42. PMID: 12191984.","DOI":"10.1097\/01.asn.0000028643.17901.42"},{"issue":"4","key":"5045_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2215\/CJN.13291019","volume":"15","author":"KL Nowak","year":"2020","unstructured":"Nowak KL, Hopp K. Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential. Clin J Am Soc Nephrol. 2020;15(4):577\u201384. doi: 10.2215\/CJN.13291019. Epub 2020 Feb 21. PMID: 32086281; PMCID: PMC7133124.","journal-title":"Clin J Am Soc Nephrol"},{"key":"5045_CR6","doi-asserted-by":"publisher","unstructured":"Mao Z, Xie G, Ong AC. Metabolic abnormalities in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2015;30(2):197\u2013203. https:\/\/doi.org\/10.1093\/ndt\/gfu044. Epub 2014 Mar 2. PMID: 24589722.","DOI":"10.1093\/ndt\/gfu044"},{"issue":"9","key":"5045_CR7","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1016\/j.ekir.2025.06.054","volume":"10","author":"N Ebrahimi","year":"2025","unstructured":"Ebrahimi N, Caliskan Y, Garimella PS, Carriazo S, Chebib FT, Bateni GH, Dahl NK, Rastogi A, Abdipour A, Norouzi S. Cardiovascular Complications in ADPKD. Kidney Int Rep. 2025;10(9):2953\u201366. PMID: 40980664; PMCID: PMC12446925.","journal-title":"Kidney Int Rep"},{"key":"5045_CR8","unstructured":"Bucci R, De Rosa LI, Brambilla Pisoni M, Farinone S, Vespa M, Joli G, Catania M, Kola K, Tunesi F, Brioni E, Carrera P, Mancassola G, Citterio L, Manunta P, Vezzoli G, Sciarrone Alibrandi MT. [The management of patients with adult autosomal dominant polycystic kidney disease (ADPKD) requires a multidisciplinary approach]. G Ital Nefrol. 2023;40(6):2023-vol6. Italian. PMID: 38156543."},{"issue":"2","key":"5045_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ekir.2024.10.043","volume":"10","author":"M Catania","year":"2024","unstructured":"Catania M, De Rosa LI, Kola K, Brambilla Pisoni M, Manunta P, Vezzoli G, Sciarrone Alibrandi MT. Early Detection Matters: Bridging Evidence and Practice, a Call for Enhanced Cardiovascular Screening in ADPKD. Kidney Int Rep. 2024;10(2):622. PMID: 39990908; PMCID: PMC11843103.","journal-title":"Kidney Int Rep"},{"key":"5045_CR10","doi-asserted-by":"publisher","unstructured":"Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5(6):1349\u201354. https:\/\/doi.org\/10.1681\/ASN.V561349. PMID: 7894001.","DOI":"10.1681\/ASN.V561349"},{"key":"5045_CR11","doi-asserted-by":"publisher","unstructured":"Barruscotti A, Moroni G, De Rosa LI, Kola K, Catania M, Tunesi F, Brambilla Pisoni M, Farinone S, Manunta P, Vezzoli G, Sciarrone Alibrandi MT. Deciphering the complexity: nephrotic syndrome in autosomal dominant polycystic kidney disease\u2014a case report and literature review. G Ital Nefrol. 2025;42(3):2025-vol3. https:\/\/doi.org\/10.69097\/42-03-2025-04. PMID: 40607823.","DOI":"10.69097\/42-03-2025-04"},{"issue":"15","key":"5045_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD, Toto RD, Langkilde AM, Wheeler DC. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816 . Epub 2020 Sep 24. PMID: 32970396.","journal-title":"N Engl J Med"},{"issue":"8","key":"5045_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","volume":"392","author":"WG Herrington","year":"2025","unstructured":"EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R, EMPA-KIDNEY Collaborative Group. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2025;392(8):777\u201387. https:\/\/doi.org\/10.1056\/NEJMoa2409183 . Epub 2024 Oct 25. PMID: 39453837; PMCID: PMC7616743.","journal-title":"N Engl J Med"},{"issue":"11","key":"5045_CR14","doi-asserted-by":"publisher","first-page":"EVIDoa2500158","DOI":"10.1056\/EVIDoa2500158","volume":"4","author":"KV Bartholdy","year":"2025","unstructured":"Bartholdy KV, Johansen ND, Skaarup KG, Modin D, Landler N, Langhoff AF, Ottosen CI, Espersen C, Dons M, Borchsenius JIM, Davodian LW, Lassen MH, Davidovski FS, Jensen AMR, Sengel\u00f8v M, Christensen J, Schou M, Feldt-Rasmussen B, Jensen J, Bressendorff I, Persson F, Rossing P, K\u00f8ber L, Zannad F, Vaduganathan M, Solomon S, Haynes R, Hansen D. Biering-S\u00f8rensen T. Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease. NEJM Evid. 2025;4(11):EVIDoa2500158. https:\/\/doi.org\/10.1056\/EVIDoa2500158 . Epub 2025 Oct 28. PMID: 41147829.","journal-title":"NEJM Evid"},{"key":"5045_CR15","doi-asserted-by":"publisher","unstructured":"Catania M, Rivera K, Kola LI, De Rosa M, Paolisi P, Bianca G, Vezzoli G, Sciarrone Alibrandi MT. SGLT2 inhibitors in ADPKD: time to integrate cardiovascular outcomes. Kidney Int Rep. 2025 Dec. https:\/\/doi.org\/10.1016\/j.ekir.2025.103762.","DOI":"10.1016\/j.ekir.2025.103762"},{"key":"5045_CR16","doi-asserted-by":"publisher","unstructured":"Bou Antoun MT, Borghol AH, Souvalian L, Hadla M, Abboud G, Ghanem A, Munairdjy Debeh FG, Mardirossian JM, Salih M, Garimella PS, Vallon V, Chebib FT. SGLT2 inhibitors in ADPKD: mechanistic insights and therapeutic promise. J Am Soc Nephrol. 2025 Nov 10. https:\/\/doi.org\/10.1681\/ASN.0000000943. Epub ahead of print. PMID: 41212622.","DOI":"10.1681\/ASN.0000000943"},{"key":"5045_CR17","doi-asserted-by":"publisher","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1016\/j.xkme.2025.101059. PMID: 40978191; PMCID: PMC12447104.","DOI":"10.1016\/j.xkme.2025.101059"},{"key":"5045_CR18","doi-asserted-by":"publisher","unstructured":"Uchiyama K, Kamano D, Nagasaka T, Hama EY, Shirai R, Sumura R, Kusahana E, Yanai A, Nakayama T, Kimura T, Takahashi R, Kasai T, Tajima T, Hosoya K, Azegami T, Yamaguchi S, Yoshino J, Ito J, Hayashi M, Kanda T, Ishibashi Y, Washida N, Itoh H, Hayashi K. Open-label randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan. Kidney Int Rep. 2025;10(4):1063\u201375. https:\/\/doi.org\/10.1016\/j.ekir.2025.01.023. Erratum in: Kidney Int Rep. 2025;10(7):2505\u20132506. doi: 10.1016\/j.ekir.2025.05.025. PMID: 40303212; PMCID: PMC12034875.","DOI":"10.1016\/j.ekir.2025.01.023"},{"issue":"4","key":"5045_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.ajkd.2017.01.046","volume":"70","author":"E Cornec-Le Gall","year":"2017","unstructured":"Cornec-Le Gall E, Audr\u00e9zet MP, Renaudineau E, Hourmant M, Charasse C, Michez E, Frouget T, Vigneau C, Dantal J, Siohan P, Longuet H, Gatault P, Ecoti\u00e8re L, Bridoux F, Mandart L, Hanrotel-Saliou C, Stanescu C, Depraetre P, Gie S, Massad M, Kersal\u00e9 A, S\u00e9ret G, Augusto JF, Saliou P, Maestri S, Chen JM, Harris PC, F\u00e9rec C, Le Meur Y. PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis. Am J Kidney Dis. 2017;70(4):476\u201385. https:\/\/doi.org\/10.1053\/j.ajkd.2017.01.046 . Epub 2017 Mar 27. PMID: 28356211; PMCID: PMC5610929.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"5045_CR20","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/ndt\/gfaf061","volume":"40","author":"RU M\u00fcller","year":"2025","unstructured":"M\u00fcller RU, Guerrot D, Chonchol M, Schmitt R, Uchiyama K, Gansevoort RT, Cornec-Le Gall E. SGLT2 inhibition for patients with ADPKD - closing the evidence gap. Nephrol Dial Transpl. 2025;40(12):2231\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfaf061 . PMID: 40199734; PMCID: PMC12648075.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"5045_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M, Takeda N, Chin-Kanasaki M, Kaneko T, Mayoux E, Mark M, Yanagita M, Ogita H, Araki SI, Maegawa H. SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. Cell Metab. 2020;32(3):404\u2013e4196. https:\/\/doi.org\/10.1016\/j.cmet.2020.06.020 . Epub 2020 Jul 28. PMID: 32726607.","journal-title":"Cell Metab"},{"issue":"12","key":"5045_CR22","doi-asserted-by":"publisher","first-page":"e088317","DOI":"10.1136\/bmjopen-2024-088317","volume":"14","author":"E Bahlmann-Kroll","year":"2024","unstructured":"Bahlmann-Kroll E, H\u00e4ckl S, Kramer S, Wulfmeyer VC, Glandorf J, Kaufeld J, Koch A, Hartung D, Schmidt BMW, Schmidt-Ott K, Schmitt R. Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial. BMJ Open. 2024;14(12):e088317. https:\/\/doi.org\/10.1136\/bmjopen-2024-088317 . PMID: 39675824; PMCID: PMC11647394.","journal-title":"BMJ Open"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05045-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:04:14Z","timestamp":1788876254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05045-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5045"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05045-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Institutional Review Board (Ethics Committee) of IRCCS San Raffaele Scientific Institute, Milan, Italy.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of clinical details was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"529"}}